Glutaric Aciduria Type I: Diagnosis and Management Approaches

Glutaric aciduria type I (GA1) is an inherited neurometabolic disorder resulting from deficiency of the mitochondrial enzyme glutaryl-CoA dehydrogenase. Impaired enzyme activity leads to accumulation of glutaric acid and 3-hydroxyglutaric acid, which precipitate acute encephalopathic crises and chronic neurotoxicity, most notably striatal injury and dystonia in early childhood. Clinical features include macrocephaly, subdural haematomas and movement disorders precipitated by catabolic stress. Early diagnosis is achieved through tandem mass spectrometry-based newborn screening programmes, detecting elevated glutarylcarnitine (C5DC) levels, supplemented by urinary organic acid profiling and confirmatory genetic testing. Management centres on lysine-restricted, arginine-enriched diets, enteral l-carnitine supplementation and prompt emergency regimens of intravenous glucose and carnitine during illness. Adherence to therapeutic protocols markedly reduces the incidence of striatal damage and supports normal growth and neurodevelopment. Emerging approaches explore pharmacological chaperones to stabilise residual enzyme, molecular insights into variant-specific misfolding and potential gene-based therapies. Despite these advances, long-term monitoring of dietary adherence, neurological outcome and cognitive function remains essential. Globally, GA1 exemplifies the impact of coordinated screening and metabolic management and underscores the need for novel interventions tailored to biochemical subtypes.

Research from Nature Portfolio

A national prospective follow-up of over 100 individuals identified by newborn screening has established that the biochemical high excreter phenotype is the principal predictor of long-term cognitive outcome in GA1. While overall IQ scores remained stable with age, high excreters achieved significantly lower performance indices than low excreters, independent of motor phenotype or quality of metabolic treatment. These findings underscore the limitations of current dietary and emergency protocols in addressing cognitive risk and highlight the need for targeted therapeutic development focused on the underlying biochemical subtype.

Glutaric Aciduria Type I: Diagnosis and Management Approaches publication trend

The graph below shows the total number of articles in glutaric aciduria type i: diagnosis and management approaches across all publications each year (not limited to Nature Index journals).

Technical terms

Glutaryl-CoA dehydrogenase (GCDH): Mitochondrial enzyme responsible for oxidative decarboxylation of glutaryl-CoA.

Newborn screening (NBS): Population-based testing of neonates, typically using tandem mass spectrometry, to detect inborn errors of metabolism.

High excreter phenotype: Biochemical subgroup of GA1 patients who exhibit markedly elevated urinary and blood levels of glutaric acid.

Pharmacological chaperone: Small molecule that binds a target enzyme to stabilise its native conformation and enhance residual activity.

C5DC (glutarylcarnitine): Acylcarnitine species measured in blood that serves as a primary biomarker for GA1 screening.

References

1. Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1. Journal of Medicinal Chemistry (2024).
2. Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1. International Journal of Molecular Sciences (2023).
3. Glutaric acidemia type 1: Treatment and outcome of 168 patients over three decades. Molecular Genetics and Metabolism (2020).
4. Subdural hematomas: glutaric aciduria type 1 or abusive head trauma? A systematic review. Forensic Science, Medicine and Pathology (2015).
5. Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: a cost-effectiveness analysis. Orphanet Journal of Rare Diseases (2013).
6. The biochemical subtype is a predictor for cognitive function in glutaric aciduria type 1: a national prospective follow-up study. Scientific Reports (2021).